Expanded Access Policy
ArriVent is a biopharmaceutical company on a mission to transform the lives of patients and their families by developing pharmaceutical therapies for patients across the globe. As a part of the drug development process, ArriVent conducts human clinical trials to show that its investigational products are safe and effective. The data from these trials are used to support marketing applications submitted to the U.S. Food and Drug Administration (FDA) and other regulatory authorities.
Under FDA regulations, expanded access to investigational new drugs may be made available to certain patients outside of the clinical trial setting. FDA permits the manufacturer of an investigational drug for the diagnosis, monitoring, or treatment of a serious or immediately life-threatening disease or condition to provide individual patients with access to the investigational drug, outside the setting of a clinical trial, if certain criteria are met. A manufacturer developing drugs for serious or life-threatening diseases or conditions that has advanced to a certain stage of development must make its policy on evaluating and responding to requests for such “expanded access” publicly and readily available.
Expanded Access Policy
ArriVent believes the best way to access its investigational products is through one of its controlled clinical trials. At this time, ArriVent is not able to grant requests for expanded access to its investigational therapies.
Clinical Trials: For more information on ArriVent’s clinical trials that may be recruiting, search “ArriVent” at www.clinicaltrials.gov.
Contact Information: A treating physician may request additional information about ArriVent’s clinical trials via email at the following address: FURMO@nullarrivent.com.
The posting of this policy by ArriVent shall not serve as a guarantee of access to any specific investigational drug by any individual patient.
ArriVent may revise this expanded access policy at any time. This posting will be updated should there be any policy change.